Ignite Creation Date:
2024-05-06 @ 8:16 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06312176
Status:
RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-03-07
Brief Title:
A Study of Sacituzumab Tirumotecan MK-2870 as a Single Agent and in Combination With Pembrolizumab MK-3475 Versus Treatment of Physicians Choice in Participants With HRHER2- Unresectable Locally Advanced or Metastatic Breast Cancer MK-2870-010
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Organization Data
Organization:
Merck Sharp Dohme LLC
Class:
INDUSTRY
Study ID:
2870-010
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck Sharp Dohme LLC
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None